Medication Description: Montelukast (Montelukast)
Sodium salt of 1 - [[[(R) -m - [(E) -2- (7-chloro-2-quinolyl) -vinyl] -α- [o- (1-hydroxy-1-methylethyl) phenethyl] benzyl ] thio] -methyl] cyclopropane acetate.
Synonym: Singular. Singular.
New bronchodilator drug, similar in action to zafirlukastu (akolat). Like zafirlukastu, is a blocker of leukotriene receptors (LTS 4 , LTD 4 , LTE 4 ) and has a bronchodilator and anti-inflammatory effect in bronchial asthma and other bronchospastic conditions.
When ingestion is quickly and completely absorbed, bioavailability is about 70%, C max -2-3 h; Biotransformation in the liver, excreted by the kidneys.
The main indications for the use of montelukast are the prevention and long-term treatment of bronchial asthma. For the relief of asthma attacks, including asthmatic status, the drug is not used.
Assign adults and adolescents (15 years and older) by mouth in the form of tablets of 0.01 g (10 mg) 1 time per day (in the evening). Children aged 6–15 years are recommended in the form of chewable tablets of 0.005 g (5 mg) once a day (in the evening). Children under the age of 5 years, the drug is not prescribed (due to lack of necessary data).
Montelukast is usually well tolerated. Possible headache, dyspeptic symptoms, swelling of the nasal mucosa, cough, increased activity (induction) of liver enzymes.
Contraindicated in pregnancy, breastfeeding, under the age of 6 years.
Treatment with montelukast, as well as with other leukotriene inhibitors and in general with new drugs, should be carried out under medical supervision. It is necessary to have ready means of rapid relief of bronchospasms in case of their occurrence. Replacement of other drugs with montelukast (glucocorticosteroids, etc.) should be made gradually. Care must be taken in appointing patients with impaired liver function.
In connection with the potential induction of liver enzymes (cytochrome P-450), the possibility of changing the pharmacokinetics (with a decrease in activity) of a number of drugs - theophylline, coumarin anticoagulants, terfenadine, etc. should be considered.
Method of production: tablets of 0.01 g (10 mg); chewable tablets of 0.005 g (5 mg) (N. 7, 14, 28).
Storage: List B, at a temperature of +15 to +30 ° C in a dry, dark place.